Odyssey Therapeutics, Inc. (ODTX)
$17.24-5.59%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $521M
- Beta
- 1.43
- P/E (TTM)
- -6.76
- Short % float
- 12.14%
- Days to cover
- 5.6
- SI change
- +40.6%
- 1W
- -4.91%
- 1M
- -28.94%
- vs SPY 1W
- -4.77%
- vs SPY 1M
- -31.44%
Industry peers
FMP comparable companies · ranked by market cap
- PTGXSELLProtagonist Therapeutics, Inc.$9.2BRECOVERYQ 32$143.73-4.41%
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 9$85.69-6.34%
- ORKASELLOruka Therapeutics, Inc.$5.0BCRISISQ -3$82.11-2.69%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95-0.98%
- ALMSSELLAlumis Inc.$884MCRISISQ 0$7.16-7.08%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ODTX?
- LOPJLB’s latest quantitative signal on Odyssey Therapeutics, Inc. (ODTX) is SELL. Signals are updated daily.
- What market regime is ODTX in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Odyssey Therapeutics, Inc. (ODTX) do?
- Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is…